Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 3/20 | 0.39 |
| ▸ | GRIN2A known ✓ | Q12879 | 3/20 | 0.39 |
| ▸ | GRIN2D known ✓ | O15399 | 2/20 | 0.35 |
| ▸ | GRIN3B known ✓ | O60391 | 2/20 | 0.35 |
| ▸ | GRIN2B known ✓ | Q13224 | 2/20 | 0.35 |
| ▸ | GRIN2C known ✓ | Q14957 | 2/20 | 0.35 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 2/20 | 0.35 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.35 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.35 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.35 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336213 | 0.98 | GRIN1 (0.37) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| SCHEMBL4040646 | 0.83 | PKM (0.36) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Hydrochloric Acid SCHEMBL22553149 | 0.83 | — | — | |
| SCHEMBL4034941 | 0.81 | PKM (0.35) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL14932913 | 0.81 | — | — | |
| SCHEMBL19766528 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL7325630 | 0.80 | GRIN1 (0.42) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| Hydrochloric Acid SCHEMBL2554902 | 0.78 | LMNA (0.55) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| SCHEMBL291709 | 0.77 | GRIN1 (0.43) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| SCHEMBL5166320 | 0.77 | GRIN1 (0.43) | GRIN1GRIN2ALMNAPMP22NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088367-A1 | Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-02 | — | — | US | claimed |
| WO-2005110468-A2 | TREATMENT OF INSULIN RESISTANCE/METABOLIC SYNDROME TO ALLEVIATE THE RISKS OF DEMENTIA | THE BURNHAM INSTITUTE (US) | 2005-11-24 | — | — | WO | claimed |
| US-6444702-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | NEUROMOLECULAR, INC. | 2002-09-03 | — | — | US | claimed |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-08-18 | — | — | US | disclosed |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| WO-2011001258-A1 | COMPOSITIONS, METHODS, AND KITS FOR TREATING VIRAL AND BACTERIAL INFECTIONS BY TOCOTRIENOLS, TOCOMONOENOLS, TOCODIENOLS, TOCOPHEROLS, AND THEIR DERIVATES | EVITA LIFE SCIENCE PTE. LTD (SG) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| US-20100137448-A1 | Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists | NEUROMOLECULAR, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20090088367-A1 | Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-02 | — | — | US | disclosed |
| US-20080183003-A1 | AMINOADAMANTANE DERIVATIVES AS THERAPEUTIC AGENTS | ADAMAS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-7326730-B2 | Neuroprotective agents; nitrate-functional, for example 1-amino-3,5-dimethyl-7-nitrateadamantane hydrochloride | ADAMAS PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20040029929-A1 | Aminoadamantane derivatives as therapeutic agents | WANG YUQIANG (US) | 2004-02-12 | — | — | US | disclosed |
| EP-1351670-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS | Neuromolecular Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6620845-B2 | For therapy and prophylaxis of neurological diseases | NEUROMOLECULAR, INC. | 2003-09-16 | — | — | US | disclosed |
| WO-2002045710-A9 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS | NEUROMOLECULAR INC (US) | 2003-04-24 | — | — | WO | disclosed |
| US-20030008889-A1 | Aminoadamantane derivatives as therapeutic agents | PANORAMA RESEARCH, INC. | 2003-01-09 | — | — | US | disclosed |
| EP-1259477-A1 | AMINOADAMANTANE DERIVATIVES AS THERAPEUTIC AGENTS | PANORAMA RESEARCH, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6444702-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | NEUROMOLECULAR, INC. | 2002-09-03 | — | — | US | disclosed |
| WO-2002045710-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS | NEUROMOLECULAR INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2001062706-A1 | AMINOADAMANTANE DERIVATIVES AS THERAPEUTIC AGENTS | PANORAMA RESEARCH, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137448-A1 | Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists | GRIN2A, GRIN1, GRIN3A | GRIN1 2/4885GRIN2A 1/4885GRIN2D 8/4885 |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | GRIN1 4826/4885GRIN2A 4854/4885GRIN2D 4867/4885 |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | GRIN1 4826/4885GRIN2A 4854/4885GRIN2D 4867/4885 |
| US-20080183003-A1 | AMINOADAMANTANE DERIVATIVES AS THERAPEUTIC AGENTS | CHRNA4, CHRNA10, BACE1 | GRIN1 287/4885GRIN2A 122/4885GRIN2D 163/4885 |
| US-20040029929-A1 | Aminoadamantane derivatives as therapeutic agents | CHRNA4, CHRNA10, BACE1 | GRIN1 287/4885GRIN2A 122/4885GRIN2D 163/4885 |
| US-20030008889-A1 | Aminoadamantane derivatives as therapeutic agents | CHRNA4, CHRNA10, BACE1 | GRIN1 287/4885GRIN2A 122/4885GRIN2D 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.